arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Insight Molecular Diagnostics Inc.

IMDX
$2.45 ▼ -0.20 (-7.55%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
48 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
55
Health
Fair
Bullish
auto_awesome

Analytical Summary

Insight Molecular Diagnostics Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $90.0M
Dividend Yield —
Revenue Growth -53.9% ↗
Op. Margin None
ROIC 42.3% ↗
FCF / Share $-0.27 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

48-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$239.00K
↓ -53.9% —
Net Income Profit after all expenses
$-11.26M
↓ -15.6% —
Operating Margin Operating profit as % of sales
-318.0%
↑ +23.2% —
FCF / Share Free cash flow per share
$-0.27
↓ -14.4% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
100
Financial Health ↓
6
Cash Quality ↓
40

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 13 years · 48 quarters